Status:

UNKNOWN

HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure

Lead Sponsor:

Parkview Medical Center

Conditions:

Heart Failure, Diastolic

Brief Summary

In a retrospective community based cohort study from Pueblo County Colorado which has a higher population proportion of metabolic syndrome and diabetes mellitus, we hope to clarify and quantify an ass...

Detailed Description

The classic association of glycemic control, as represented by HBa1c, with progression or improvement of microvascular and macrovascular clinical complications has been well documented. Additionally, ...

Eligibility Criteria

Inclusion

  • Stage A heart failure on basis of metabolic criteria

Exclusion

  • LV dysfunction, valvular heart disease, hypertension and CAD

Key Trial Info

Start Date :

December 20 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2020

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04450576

Start Date

December 20 2019

End Date

December 30 2020

Last Update

November 16 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Parkview Medical Center

Pueblo, Colorado, United States, 81003

HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure | DecenTrialz